AU2015360761B2 - Treatment of breast cancer with liposomal irinotecan - Google Patents

Treatment of breast cancer with liposomal irinotecan Download PDF

Info

Publication number
AU2015360761B2
AU2015360761B2 AU2015360761A AU2015360761A AU2015360761B2 AU 2015360761 B2 AU2015360761 B2 AU 2015360761B2 AU 2015360761 A AU2015360761 A AU 2015360761A AU 2015360761 A AU2015360761 A AU 2015360761A AU 2015360761 B2 AU2015360761 B2 AU 2015360761B2
Authority
AU
Australia
Prior art keywords
irinotecan
breast cancer
patient
dose
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015360761A
Other languages
English (en)
Other versions
AU2015360761A1 (en
Inventor
Eliel Bayever
Jonathan Basil Fitzgerald
Jaeyeon Kim
Stephan Klinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of AU2015360761A1 publication Critical patent/AU2015360761A1/en
Application granted granted Critical
Publication of AU2015360761B2 publication Critical patent/AU2015360761B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2015360761A 2014-12-09 2015-12-08 Treatment of breast cancer with liposomal irinotecan Ceased AU2015360761B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089685P 2014-12-09 2014-12-09
US62/089,685 2014-12-09
PCT/US2015/064491 WO2016094402A1 (en) 2014-12-09 2015-12-08 Treatment of breast cancer with liposomal irinotecan

Publications (2)

Publication Number Publication Date
AU2015360761A1 AU2015360761A1 (en) 2017-06-15
AU2015360761B2 true AU2015360761B2 (en) 2021-05-20

Family

ID=54979964

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015360761A Ceased AU2015360761B2 (en) 2014-12-09 2015-12-08 Treatment of breast cancer with liposomal irinotecan

Country Status (6)

Country Link
US (2) US20160346272A1 (enExample)
EP (1) EP3229802A1 (enExample)
JP (3) JP7113619B2 (enExample)
AU (1) AU2015360761B2 (enExample)
HK (1) HK1245133A1 (enExample)
WO (1) WO2016094402A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
BR112018002941B1 (pt) * 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
RS67289B1 (sr) 2015-10-16 2025-11-28 Ipsen Biopharm Ltd Stabilizacija farmaceutskih kompozicija kamptotecina
WO2018083470A1 (en) 2016-11-02 2018-05-11 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin)
KR20210040997A (ko) * 2018-08-05 2021-04-14 다 볼떼라 항암제 효능의 개선 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20070110798A1 (en) * 2004-05-03 2007-05-17 Hermes Biosciences, Inc. Liposomes useful for drug delivery to the brain
WO2012012454A1 (en) * 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
WO2014113167A1 (en) * 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI283575B (en) * 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2005107712A1 (en) 2004-05-03 2005-11-17 Hermes Biosciences, Inc. Liposomes useful for drug delivery
EP2004175A4 (en) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
CA2992789A1 (en) * 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
BR112018002941B1 (pt) * 2015-08-21 2023-12-05 Ipsen Biopharm Ltd Uso de irinotecano lipossomal, oxaliplatina, leucovorina e 5- fluorouracil no tratamento de primeira linha de adenocarcinoma metastático do pâncreas
RS67289B1 (sr) * 2015-10-16 2025-11-28 Ipsen Biopharm Ltd Stabilizacija farmaceutskih kompozicija kamptotecina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20070110798A1 (en) * 2004-05-03 2007-05-17 Hermes Biosciences, Inc. Liposomes useful for drug delivery to the brain
WO2012012454A1 (en) * 2010-07-19 2012-01-26 Bipar Sciences, Inc. Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan
WO2014113167A1 (en) * 2012-12-14 2014-07-24 Merrimack Pharmaceuticals, Inc. Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents

Also Published As

Publication number Publication date
WO2016094402A1 (en) 2016-06-16
HK1245133A1 (zh) 2018-08-24
US20160346272A1 (en) 2016-12-01
JP2017537124A (ja) 2017-12-14
EP3229802A1 (en) 2017-10-18
AU2015360761A1 (en) 2017-06-15
JP2020073601A (ja) 2020-05-14
JP2022079545A (ja) 2022-05-26
JP7113619B2 (ja) 2022-08-05
US20200360367A1 (en) 2020-11-19

Similar Documents

Publication Publication Date Title
AU2015360761B2 (en) Treatment of breast cancer with liposomal irinotecan
US20240226090A1 (en) Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan
KR20150126038A (ko) 폐암의 치료 방법
KR20170086706A (ko) 소세포 폐암의 치료 방법
US20190142822A1 (en) Treatment of Breast Cancer with Liposomal Irinotecan
RU2808427C2 (ru) Способы лечения рака поджелудочной железы с применением комбинированной терапии, включающей липосомальный иринотекан

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired